Fetal Embolization for Vein of Galen Malformation

This trial explores a potential treatment for a rare condition called vein of Galen malformation (VOGM), which affects blood vessels in a fetus's brain. The study evaluates whether fetal embolization, a minimally invasive procedure performed before birth, can safely and effectively treat this condition. Pregnant women carrying a fetus diagnosed with VOGM at or after 34 weeks of gestation may qualify, especially if certain blood vessel measurements meet the study's criteria. Researchers will monitor the child's neurological development for two years after the procedure to compare outcomes with past cases. As an unphased trial, this study offers a unique opportunity to contribute to groundbreaking research that could improve outcomes for future patients.

The trial requires that you do not use any anticoagulants (medications that prevent blood clotting) during the study.

Research has shown that fetal embolization holds promise for treating a rare brain blood vessel condition called vein of Galen malformation. One study found that three out of five babies who received this treatment survived beyond the newborn stage without developmental delays, suggesting the procedure might be safe. Another report from early clinical trials at Boston Children's Hospital indicated improved survival rates with this treatment. While these results are hopeful, they come from a small number of cases. It's important to remember that researchers are still studying the treatment for its safety and effectiveness.¹²³⁴⁵

Fetal embolization is unique because it offers a prenatal approach to treating vein of Galen malformation, a rare and serious condition usually addressed after birth. Most current treatments involve postnatal surgical interventions, which can be risky and less effective due to the progression of the condition. By intervening during fetal development, this method aims to prevent complications before they arise, potentially reducing the severity of symptoms and improving long-term outcomes. Researchers are excited because this approach could revolutionize how we manage the condition, offering hope for better quality of life from the very start.

Research has shown that treating Vein of Galen malformation in unborn babies can greatly improve their health. In earlier studies, five out of seven babies received this treatment successfully, reducing the chance of newborn death from 90% to 43%. Additionally, 62% of treated babies experienced better brain development as they grew. One baby even demonstrated immediate benefits, such as a 40% decrease in heart strain before birth. Overall, this treatment has shown promise in lowering risks and improving life quality for those with this condition. Participants in this trial will undergo a one-time intervention of fetal embolization for Vein of Galen malformation, as part of a single-arm study.²⁴⁵⁶⁷